Kurt Losert 
A new clinical trial of an immune therapy for fibrolamellar carcinoma (FLC) is now recruiting subjects at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, MD. The study asks if individuals can mount an effective immune response against FLC by specifically targeting the unique chimeric protein …
The Fibrolamellar Cancer Foundation (FCF) is proud to announce The Mark Foundation for Cancer Research has awarded their coveted Aspire Award to Dr. Paul Thomas, St. Jude Children’s Research Hospital for fibrolamellar carcinoma immunotherapy research. The Aspire Award …
The Chan Zuckerberg Initiative (CZI) announced that the Fibrolamellar Cancer Foundation (FCF) is among a select group of patient-led rare disease organizations, including rare cancer foundations, to receive the first CZI Rare As One Network grant…
Big thanks to Jenny Carroll, Jennifer Strickland and all in the FLC community who participated in the 2019 Department of Defense grant reviews. Since liver cancer has been an approved cancer for DOD funding, Fibrolamellar has been awarded over $2 million in support…
FCF Press Release on Rare Disease Day Tuesday October 1, 2019 is Rare Cancer Day. The event this year is especially important because at the Fibrolamellar Cancer Foundation (FCF) we are celebrating ten years of bringing awareness to this disease. We are proud to have contributed nearly $8 million to researching cures and treatments for …
Nearly 80 members of the fibrolamellar scientific community – USA and international- gathered in Greenwich, CT in early November to share their research, discoveries and hopes for curative therapies. Importantly those attending embrace collaboration and data sharing – even if their research is not published …
A successful liver transplant can be life-saving for patients facing liver failure and there are thousands of people currently waiting to receive transplants. Since the liver is the only organ that can regenerate itself and grow from a small piece back to its full size, a living donor can volunteer to divide their healthy liver …
Nancy A. Berryhill, Acting Commissioner of Social Security, announced five new Compassionate Allowance conditions: Fibrolamellar Cancer, Megacystis Microcolon Intestinal Hypoperistalsis Syndrome (MMIHS), Megalencephaly Capillary Malformation Syndrome (MCAP), Superficial Siderosis of the Central Nervous System, and …
The Fibrolamellar Research Collaboration Travel Fund has officially launched, following the second international fibrolamellar (FLC) research summit hosted by the FCF. The summit fostered an amazing amount of data sharing and collaborative brainstorming amongst some of the world’s greatest researchers…